Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price ...

Medtronic (NYSE: MDT) has named Jorie Soskin as its new VP and GM of its TAVR and Congenital Heart businesses.

Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy Axonics, which was announced in January.

A month has gone by since the last earnings report for Medtronic (MDT). Shares have added about 0.7% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's ...

During the quarter, broad U.S. equity markets rose amid moderating inflation, strong corporate earnings growth and weakening ...

According to GlobalData, the decision of the US regulator is likely to hurt Medtronic's sales, which currently occupies ...

Merit predicts the portfolio, which includes devices used in procedures to remove or replace heart rhythm device leads, will add $40 million a year to its sales.

The seriousness of this latest recall can be expected to have a noticeable effect on Medtronic’s laryngoscope sales.

BlueWind Medical, a pioneer in implantable Tibial NeuroModulation (iTNM) and the developer of Revi®, a patient-centric ...

Epitomee's Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for ...

Medtronic, a global developer and manufacturer of medical devices for chronic diseases, is now a $111 billion (by market cap) ...